1. Date of download: 7/11/2016 From: Safety of Herpes Zoster Vaccine in the Shingles Prevention Study: A Randomized Trial Ann Intern Med. 2010;152(9):545-554. doi:10.7326/0003-4819-152-9-201005040-00004 Safety monitoring in the Shingles Prevention Study.* Enrollment into the adverse event substudy was independent of blinded random assignment to receive vaccine or placebo. During the first year of the study, we completed a convenience sample of 300 participants per site, with a target of 50% in each age group. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

2. Date of download: 7/11/2016 From: Safety of Herpes Zoster Vaccine in the Shingles Prevention Study: A Randomized Trial Ann Intern Med. 2010;152(9):545-554. doi:10.7326/0003-4819-152-9-201005040-00004 Time to first SAE from day 0 to day 42 for the total study population.The cumulative rates of SAEs are shown for the time to the first SAE from days 0 to 42 after inoculation in all study participants. There is no significant treatment difference within age strata: For persons aged 60 to 69 years, log-rank P = 0.41; for persons 70 years or older, log-rank P = 0.56. Overall treatment comparison: log-rank P = 0.94. Comparison of age strata 60 to 69 years versus 70 years or older: log-rank P < 0.001. SAE = serious adverse event. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

3. Date of download: 7/11/2016 From: Safety of Herpes Zoster Vaccine in the Shingles Prevention Study: A Randomized Trial Ann Intern Med. 2010;152(9):545-554. doi:10.7326/0003-4819-152-9-201005040-00004 Cumulative mortality rates for the total study population, by age stratum and treatment group.Cumulative mortality rate is shown for the time to death in all study participants. There is no significant treatment difference within age strata: For persons aged 60 to 69 years, log-rank P = 0.20; for persons 70 years or older, log-rank P = 0.37. Overall treatment comparison: log-rank P = 0.95. Comparison of age strata 60 to 69 years versus 70 years or older: log-rank P < 0.001. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians

4. Date of download: 7/11/2016 From: Safety of Herpes Zoster Vaccine in the Shingles Prevention Study: A Randomized Trial Ann Intern Med. 2010;152(9):545-554. doi:10.7326/0003-4819-152-9-201005040-00004 Time to first hospitalization for participants in the adverse events substudy, by age stratum and treatment group.Cumulative hospitalization rate is shown for the first hospital admission occurring for participants in the adverse events substudy. There is no significant treatment difference within age strata: For persons aged 60 to 69 years, log-rank P = 0.77; for persons 70 years or older, log-rank P = 0.55. Overall treatment comparison: log-rank P = 0.80. Comparison of age strata 60 to 69 years versus 70 years or older: log-rank P < 0.001. Figure Legend: Copyright © American College of Physicians. All rights reserved.American College of Physicians